UK - Residential Clinic

Looking for a rehab clinic/treatment centre in the UK area?

You can receive independent, expert advice on alcohol rehabilitation and rehab centres by telephoning directly on 0117 339 0080.

The most important consideration in choosing a rehab centre is to match the individual to the rehab centre that is most likely to lead to a successful outcome.

We can provide an assessment of all your needs and a recommendation regarding the most effective rehab placement for you, given your particular circumstances. We can provide fast, immediate access to alcohol treatment.

Rehab News:Novel compound shows promise for treatment of alcoholism

Southern Research Institute and Gallo Research Center recently announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry. The publication is available online now at the journal's website, and suggests that a new compound that causes selective and long-lasting reduction in ethanol consumption might be a promising candidate as a novel treatment for alcoholism.

The article presents the effects of SoRI-9409 on ethanol consumption. These are promising developments for the treatment of alcoholism. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) estimates 15.1 million people are alcohol-abusing or alcohol-dependent individuals. There are currently only three FDA-approved options for the treatment of alcoholism.

The compound, SoRI-9409, was first designed and synthesised in Southern Research's Drug Discovery research division by Dr. Subramaniam (Sam) Ananthan under U.S. Government Grant DA008883. "Southern Research has been particularly interested in ligands that interact with opioid delta receptor subtype since such ligands hold promise as therapeutic agents for treatment of drug addictions and other disorders," said Dr. Ananthan, senior scientist and manager of Computational Chemistry and CNS Discovery Chemistry at Southern Research Institute. "The present findings by Dr. Bartlett and her group on the effect of SoRI-9409 on its ability to reduce alcohol intake not only provides us with a new drug lead, but also serves as the impetus for further research aimed at discovery of new therapeutic compounds for treating alcoholism and related disorders."

The Preclinical Development Group that Dr. Bartlett leads at the UCSF-affiliated Gallo Center was established to develop new treatments and bridge the gap between research and clinical treatment. The purpose of the study was to find improved compounds for the treatment of alcoholism. "The study results demonstrate that this compound causes selective and long-lasting reductions of ethanol consumption and suggests the compound might be a promising candidate as a novel treatment for alcoholism. This study indicates that compounds with a higher affinity for delta opioid receptors and reduced affinity for mu opioid receptors might be better treatment candidates than Naltrexone, the current FDA approved treatment for alcoholism", said Dr. Bartlett.

"The study on SoRI-9409 and alcohol cessation has yielded vital data that will help fuel novel treatments for a devastating and very difficult-to-treat illness," said Dr. Bartlett. "To date, we have considered and evaluated other compounds, and theories, but the information yielded from this study, along with previous research on this particular compound, has proven to be the most promising to date. We are looking forward to collaborating with our partner, Southern Research, to enter the next phase of research."

First author on the paper is Carsten Nielsen, PhD, a postdoctoral scientist working with Bartlett. Co-authors are Jeffrey A. Simms, Haley B. Pierson, Rui Li at the Gallo Clinic and Research Center and Surendra K. Saini and Subramaniam (Sam) Ananthan at Southern Research Institute.

Reference

Nielsen et al., A Novel Delta Opioid Receptor Antagonist, SoRI-9409, Produces a Selective and Long-Lasting Decrease in Ethanol Consumption in Heavy-Drinking Rats', Biological Psychiatry, to be published in December 2008.

• Technology improves treatment options for drug users ...... read
• Socially stable individuals delay seeking help for alcohol problems ...... read
• Alkermes initiates clinical trial for ALKS 33, a novel oral molecule with potential benefits in addi ...... read
• Programme to deter youth alcohol use also reduces conduct problems ...... read
• Potential new drug for cocaine addiction and overdose, Journal of the American Chemical Society ...... read
• Are you a binge drinker, BMA Scotland calls for compulsory labelling of alcoholic drinks ...... read
• Top researchers to explore stress and anxiety, trauma, poverty and addiction seminar ...... read
• Avigen initiates opioid withdrawal trial ...... read
• Treatment alternative for drug offenders has had some success ...... read
• Les Ferdinand kicks off project to help those with drug and alcohol problems ...... read
• Ability to quit smoking may depend on ADHD symptoms, researchers find ...... read
• Positive environment can help drug addiction ...... read
• Hope for treating relapse to methamphetamine abuse ...... read
• Blocking a neuropeptide receptor decreases nicotine addiction ...... read
• New nationwide report reveals that 5 Million people participate in self help groups each year ...... read
• New charity partnership looks to support service users with complex needs ...... read
• Effects of cocaine use on mother infant relationships studied by UNC, Yale partnership ...... read
• Extended treatment with combination medication for opioid addicted youths shows benefit ...... read
• Extended treatment with combination medication for opioid addicted youths shows benefit ...... read
• Families, friends, schools and neighbourhoods contribute to adolescent alcohol misuse ...... read